CAPR
Capricor Therapeutics, Inc.·Healthcare
31.20
1.297%(−0.41)
Market ClosedLast Updated: — ET
52W L: $4.3052W H: $40.37
CAPR NEWS
defenseworld.net
Apr 3
Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 25,000 Shares of Stock
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) CFO Anthony Bergmann sold 25,000 shares of the firm's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares
defenseworld.net
Apr 3
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 61,265 Shares
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) Director Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a filing with the Securities and
defenseworld.net
Apr 3
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 53,735 Shares of Stock
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) Director Karimah Es Sabar sold 53,735 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05. The transaction was disclosed in a document filed with the Securities and Exchange
defenseworld.net
Mar 31
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average – What’s Next?
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $26.80 and traded as high as $29.27. Capricor Therapeutics shares last traded at $27.77, with a volume of 745,376 shares traded. Wall Street Analyst
defenseworld.net
Mar 15
Contrasting Zimmer Biomet (NYSE:ZBH) and Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Profitability This table compares Capricor Therapeutics and Zimmer
seekingalpha.com
Mar 13
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
Capricor Therapeutics is upgraded from 'Hold' to 'Buy' following FDA acceptance of the HOPE-3 clinical study report for Deramiocel in DMD cardiomyopathy. The FDA lifted the Complete Response Letter and set a PDUFA date of August 22, 2026, without requiring new studies, increasing regulatory clarity. Phase 3 HOPE-3 data showed Deramiocel slowed disease progression by 54% [PUL] and 91% [LVEF], with additional functional and fibrosis benefits.
